Skip to main content

Table 1 Baseline clinical characteristic of the 156 patients with cerebral malaria in both treatment arms on admission.

From: Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: A randomized clinical trial

Variable Placebo
N = 80
Mannitol
N = 76
P value
Female 42(52.5%) 34(44.7%) 0.33
Fever 79(98.8) 76 (100%) 0.33
Convulsions 79(98.8%) 75(98.7%) 0.97
Duration of coma 7.0 (IQR3.5–12.0) 6.0 (5.0–12.0) 0.79
Blantyre coma score 1/5 13(16.2%) 10(13.2%) 0.59
Abnormal fundoscopic changesa 28(35.0%)) 16(21.1%) 0.53
Papilloedema 3(3.8%) 5(6.6%) 0.42
Sodium – mmol/l (SD) 133.8 (4.2) 130.9 (14.8) 0.09
Hb – g/dl (SD) 7.1 (1.8) 7.1 (1.9) 0.98
Parasite density/μL (IQR) 37000(5390–115760) 58860(12390–284590) 0.05
  1. IQR Inter Quartile Range
  2. aAbnormal fundoscopic changes (congested retinal veins, blurred disc margins, papilloema, retinal haemorrhages) indicative of raised intracranial pressure